Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This research is being conducted to look at the effects of an intraocular drug (pegaptanib,
also called Macugen) for the treatment of swelling in the retina (the light sensitive tissue
in the back of the eye) that often occurs following cataract surgery in patients with
diabetic eye disease. Swelling in the retina can lead to blurry vision, and Macugen may
reduce this swelling. Eyedrops that decrease inflammation also may help to stop some of the
swelling. We are testing this drug (pegaptanib) to see if it can decrease swelling in the
retina and improve vision in patients with diabetes who are having cataract surgery.